<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes">
    <meta name="apple-mobile-web-app-capable" content="yes">
    <title>ABIM Hematology/Oncology Study Guide</title>
    <style>
        * { box-sizing: border-box; -webkit-tap-highlight-color: rgba(220, 38, 38, 0.2); }
        body { font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, sans-serif; line-height: 1.6; color: #1e293b; max-width: 1200px; margin: 0 auto; padding: 20px; padding-bottom: 80px; background: linear-gradient(135deg, #fef2f2 0%, #fff1f2 100%); min-height: 100vh; }
        h1 { color: #dc2626; border-bottom: 3px solid #dc2626; padding-bottom: 10px; font-size: 1.75rem; }
        h2 { color: #b91c1c; border-bottom: 2px solid #fecaca; padding-bottom: 8px; margin-top: 0; font-size: 1.4rem; }
        h3 { color: #991b1b; margin-top: 20px; font-size: 1.15rem; border-left: 4px solid #dc2626; padding-left: 12px; }
        h4 { color: #7f1d1d; margin-top: 15px; font-size: 1rem; }
        .header-box { background: linear-gradient(135deg, #dc2626 0%, #ef4444 50%, #f87171 100%); color: white; padding: 30px 24px; border-radius: 16px; margin-bottom: 24px; text-align: center; box-shadow: 0 4px 20px rgba(220, 38, 38, 0.3); }
        .header-box h1 { color: white; border: none; margin: 0; font-size: 1.9rem; }
        .header-box .subtitle { font-size: 1rem; opacity: 0.95; margin-top: 8px; }
        .header-box .build-tag { display: inline-block; background: rgba(255,255,255,0.2); padding: 4px 14px; border-radius: 20px; font-size: 0.85rem; margin-top: 12px; }
        .search-container { padding: 16px 20px; background: white; border-radius: 12px; margin-bottom: 20px; box-shadow: 0 2px 8px rgba(0,0,0,0.06); }
        .search-box { width: 100%; padding: 14px 20px; border: 2px solid #fecaca; border-radius: 25px; font-size: 1rem; outline: none; }
        .search-box:focus { border-color: #dc2626; box-shadow: 0 0 0 3px rgba(220, 38, 38, 0.15); }
        .nav-container { position: sticky; top: 0; z-index: 100; background: rgba(254, 242, 242, 0.95); backdrop-filter: blur(10px); padding: 12px 0; margin: 0 -20px 20px -20px; padding-left: 20px; padding-right: 20px; border-bottom: 1px solid #fecaca; }
        .nav-pills { display: flex; overflow-x: auto; gap: 8px; padding-bottom: 8px; -webkit-overflow-scrolling: touch; scrollbar-width: none; }
        .nav-pills::-webkit-scrollbar { display: none; }
        .nav-pill { flex-shrink: 0; padding: 10px 18px; background: white; color: #b91c1c; text-decoration: none; border-radius: 22px; font-size: 0.9rem; font-weight: 500; border: 2px solid #fecaca; white-space: nowrap; }
        .nav-pill:hover, .nav-pill:active { background: #dc2626; color: white; border-color: #dc2626; }
        .section { background: white; margin-bottom: 20px; padding: 24px; border-radius: 12px; border-left: 5px solid #dc2626; box-shadow: 0 2px 8px rgba(0,0,0,0.06); }
        .section-header { cursor: pointer; display: flex; justify-content: space-between; align-items: center; }
        .section-header::after { content: '‚ñº'; font-size: 0.8rem; color: #dc2626; transition: transform 0.3s ease; }
        .section.collapsed .section-header::after { transform: rotate(-90deg); }
        .section.collapsed .section-content { display: none; }
        .section-content { margin-top: 16px; }
        table { width: 100%; border-collapse: collapse; margin: 16px 0; font-size: 0.9rem; }
        th, td { border: 1px solid #fecaca; padding: 12px; text-align: left; }
        th { background: linear-gradient(135deg, #dc2626 0%, #ef4444 100%); color: white; font-weight: 600; }
        tr:nth-child(even) { background: #fef2f2; }
        tr:hover { background: #fee2e2; }
        ul, ol { margin: 12px 0; padding-left: 24px; }
        li { margin: 8px 0; }
        .high-yield { background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%); border: 2px solid #f59e0b; border-radius: 10px; padding: 16px; margin: 16px 0; }
        .high-yield::before { content: "‚≠ê HIGH-YIELD: "; font-weight: 700; color: #d97706; }
        .clinical-pearl { background: linear-gradient(135deg, #dbeafe 0%, #e0f2fe 100%); border: 2px solid #3b82f6; border-radius: 10px; padding: 16px; margin: 16px 0; }
        .clinical-pearl::before { content: "üíé CLINICAL PEARL: "; font-weight: 700; color: #2563eb; }
        .danger-box { background: linear-gradient(135deg, #fee2e2 0%, #fecaca 100%); border: 2px solid #ef4444; border-radius: 10px; padding: 16px; margin: 16px 0; }
        .danger-box::before { content: "üö® DANGER: "; font-weight: 700; color: #dc2626; }
        .mnemonic-box { background: linear-gradient(135deg, #d1fae5 0%, #a7f3d0 100%); border: 2px solid #10b981; border-radius: 10px; padding: 16px; margin: 16px 0; }
        .mnemonic-box::before { content: "üß† MNEMONIC: "; font-weight: 700; color: #059669; }
        .guideline-box { background: linear-gradient(135deg, #f3e8ff 0%, #ede9fe 100%); border: 2px solid #8b5cf6; border-radius: 10px; padding: 16px; margin: 16px 0; }
        .guideline-box::before { content: "üìã GUIDELINE: "; font-weight: 700; color: #7c3aed; }
        .badge { display: inline-block; padding: 3px 10px; border-radius: 12px; font-size: 0.75rem; font-weight: 600; margin-left: 8px; }
        .badge-common { background: #dbeafe; color: #1d4ed8; }
        .badge-danger { background: #fee2e2; color: #dc2626; }
        .badge-boards { background: #fef3c7; color: #d97706; }
        .back-to-top { position: fixed; bottom: 30px; right: 30px; width: 56px; height: 56px; background: linear-gradient(135deg, #dc2626 0%, #ef4444 100%); color: white; border: none; border-radius: 50%; font-size: 1.5rem; cursor: pointer; box-shadow: 0 4px 15px rgba(220, 38, 38, 0.4); display: none; align-items: center; justify-content: center; z-index: 1000; }
        .back-to-top.show { display: flex; }
        footer { background: linear-gradient(135deg, #dc2626 0%, #ef4444 50%, #f87171 100%); color: white; padding: 30px 24px; border-radius: 16px; margin-top: 40px; text-align: center; }
        footer a { color: white; text-decoration: none; background: rgba(255,255,255,0.2); padding: 10px 20px; border-radius: 22px; margin: 6px; display: inline-block; font-size: 0.9rem; }
        @media (min-width: 768px) and (max-width: 1024px) { body { padding: 24px 28px; } .section { padding: 28px; } }
        @media (max-width: 767px) { .header-box h1 { font-size: 1.5rem; } .section { padding: 18px; } table { font-size: 0.8rem; } th, td { padding: 8px; } }
        @media (pointer: coarse) { .nav-pill, .section-header, button { min-height: 44px; } }
    </style>
</head>
<body>

<div class="header-box">
    <h1>ü©∏ ABIM Hematology/Oncology Study Guide</h1>
    <div class="subtitle">High-Yield Board Review ‚Ä¢ ASH/ASCO/NCCN Guidelines</div>
    <div class="build-tag">BUILD #1 ‚Ä¢ 50 SECTIONS ‚Ä¢ DECEMBER 2025</div>
</div>

<div class="search-container">
    <input type="text" class="search-box" id="searchBox" placeholder="Search topics, conditions, medications..." autocomplete="off">
</div>

<nav class="nav-container">
    <div class="nav-pills">
        <a href="#anemia" class="nav-pill">Anemia</a>
        <a href="#bleeding" class="nav-pill">Bleeding</a>
        <a href="#thrombosis" class="nav-pill">Thrombosis</a>
        <a href="#wbc" class="nav-pill">WBC Disorders</a>
        <a href="#lymphoma" class="nav-pill">Lymphoma</a>
        <a href="#leukemia" class="nav-pill">Leukemia</a>
        <a href="#myeloma" class="nav-pill">Myeloma</a>
        <a href="#mpn" class="nav-pill">MPN</a>
        <a href="#transfusion" class="nav-pill">Transfusion</a>
        <a href="#oncology" class="nav-pill">Onc Emergencies</a>
    </div>
</nav>

<!-- SECTION 1: IRON DEFICIENCY ANEMIA -->
<div class="section" id="anemia">
    <div class="section-header">
        <h2>1. Iron Deficiency Anemia <span class="badge badge-common">Very Common</span></h2>
    </div>
    <div class="section-content">
        <h3>Etiology</h3>
        <ul>
            <li><strong>Blood loss:</strong> GI (most common in men/postmenopausal women), menstrual (premenopausal women)</li>
            <li><strong>Decreased absorption:</strong> Celiac, gastric bypass, H. pylori, PPI use</li>
            <li><strong>Increased demand:</strong> Pregnancy, growth</li>
            <li><strong>Dietary:</strong> Rare in developed countries</li>
        </ul>
        
        <h3>Laboratory Findings</h3>
        <table>
            <tr><th>Test</th><th>Finding</th></tr>
            <tr><td>MCV</td><td>‚Üì (microcytic)</td></tr>
            <tr><td>Ferritin</td><td><strong>‚Üì (most specific)</strong></td></tr>
            <tr><td>Serum iron</td><td>‚Üì</td></tr>
            <tr><td>TIBC</td><td>‚Üë</td></tr>
            <tr><td>Transferrin saturation</td><td>‚Üì (<20%)</td></tr>
            <tr><td>RDW</td><td>‚Üë</td></tr>
            <tr><td>Peripheral smear</td><td>Microcytic, hypochromic, target cells</td></tr>
        </table>
        
        <div class="clinical-pearl">
            Ferritin is an acute phase reactant. May be falsely normal/elevated in inflammation. If ferritin 30-100 ng/mL with inflammation, still consider iron deficiency.
        </div>
        
        <h3>Workup</h3>
        <ul>
            <li>Men and postmenopausal women: <strong>GI evaluation mandatory</strong> (upper and lower endoscopy)</li>
            <li>Premenopausal women: GI workup if heavy menses don't explain, or if >50 or GI symptoms</li>
            <li>Celiac serology if malabsorption suspected</li>
        </ul>
        
        <h3>Treatment</h3>
        <ul>
            <li><strong>Oral iron:</strong> Ferrous sulfate 325mg (65mg elemental) daily-TID; take on empty stomach with vitamin C</li>
            <li><strong>IV iron:</strong> If intolerant, malabsorption, ongoing blood loss, or need rapid repletion</li>
            <li>Reticulocyte response in 1 week; Hgb increase in 2-4 weeks</li>
            <li>Continue 3-6 months after Hgb normalizes to replete stores</li>
        </ul>
    </div>
</div>

<!-- SECTION 2: ANEMIA OF CHRONIC DISEASE -->
<div class="section" id="acd">
    <div class="section-header">
        <h2>2. Anemia of Chronic Disease <span class="badge badge-common">Common</span></h2>
    </div>
    <div class="section-content">
        <h3>Pathophysiology</h3>
        <ul>
            <li>Inflammatory cytokines ‚Üí increased hepcidin</li>
            <li>Hepcidin blocks iron release from macrophages and absorption</li>
            <li>Functional iron deficiency despite adequate stores</li>
        </ul>
        
        <h3>Laboratory Findings</h3>
        <table>
            <tr><th>Test</th><th>ACD</th><th>Iron Deficiency</th><th>ACD + Iron Def</th></tr>
            <tr><td>Ferritin</td><td>‚Üë or normal</td><td>‚Üì</td><td>Low-normal</td></tr>
            <tr><td>Serum iron</td><td>‚Üì</td><td>‚Üì</td><td>‚Üì</td></tr>
            <tr><td>TIBC</td><td>‚Üì or normal</td><td>‚Üë</td><td>‚Üì or normal</td></tr>
            <tr><td>Transferrin sat</td><td>‚Üì</td><td>‚Üì</td><td>‚Üì</td></tr>
        </table>
        
        <h3>Treatment</h3>
        <ul>
            <li>Treat underlying condition</li>
            <li>ESAs (erythropoietin) in CKD, cancer-related anemia</li>
            <li>IV iron if concurrent iron deficiency</li>
            <li>Transfusion if symptomatic</li>
        </ul>
    </div>
</div>

<!-- SECTION 3: MACROCYTIC ANEMIA -->
<div class="section" id="macrocytic">
    <div class="section-header">
        <h2>3. Macrocytic Anemia <span class="badge badge-boards">High-Yield</span></h2>
    </div>
    <div class="section-content">
        <h3>Causes</h3>
        <table>
            <tr><th>Megaloblastic</th><th>Non-Megaloblastic</th></tr>
            <tr><td>B12 deficiency</td><td>Alcoholism</td></tr>
            <tr><td>Folate deficiency</td><td>Liver disease</td></tr>
            <tr><td>Drugs (methotrexate, hydroxyurea)</td><td>Hypothyroidism</td></tr>
            <tr><td></td><td>MDS</td></tr>
            <tr><td></td><td>Reticulocytosis</td></tr>
        </table>
        
        <h3>B12 Deficiency</h3>
        <h4>Causes</h4>
        <ul>
            <li><strong>Pernicious anemia:</strong> Anti-intrinsic factor antibodies (most specific), anti-parietal cell Ab</li>
            <li>Gastric surgery, atrophic gastritis</li>
            <li>Ileal resection or disease (Crohn's)</li>
            <li>Metformin (long-term use)</li>
            <li>Strict veganism</li>
        </ul>
        
        <h4>Clinical Features</h4>
        <ul>
            <li><strong>Hematologic:</strong> Megaloblastic anemia, pancytopenia, hypersegmented neutrophils</li>
            <li><strong>Neurologic:</strong> Subacute combined degeneration (posterior columns + lateral corticospinal tracts), peripheral neuropathy, cognitive changes</li>
            <li><strong>Glossitis</strong></li>
        </ul>
        
        <div class="danger-box">
            Neurologic symptoms can occur <strong>without anemia</strong>. Low-normal B12 (200-400 pg/mL) with symptoms ‚Üí check methylmalonic acid (elevated in B12 deficiency, normal in folate deficiency).
        </div>
        
        <h3>Folate Deficiency</h3>
        <ul>
            <li><strong>Causes:</strong> Dietary (alcoholism), malabsorption, increased demand (pregnancy, hemolysis), drugs (phenytoin, TMP-SMX)</li>
            <li>No neurologic symptoms (unlike B12)</li>
            <li>Elevated homocysteine; normal MMA</li>
        </ul>
        
        <div class="high-yield">
            <strong>Never give folate alone if B12 status unknown!</strong> Folate can correct anemia but worsen neurologic damage in B12 deficiency.
        </div>
    </div>
</div>

<!-- SECTION 4: HEMOLYTIC ANEMIA -->
<div class="section" id="hemolysis">
    <div class="section-header">
        <h2>4. Hemolytic Anemia ‚Äî Overview <span class="badge badge-boards">High-Yield</span></h2>
    </div>
    <div class="section-content">
        <h3>Laboratory Findings</h3>
        <table>
            <tr><th>Test</th><th>Finding</th></tr>
            <tr><td>Reticulocyte count</td><td>‚Üë (appropriately responding marrow)</td></tr>
            <tr><td>LDH</td><td>‚Üë</td></tr>
            <tr><td>Indirect bilirubin</td><td>‚Üë</td></tr>
            <tr><td>Haptoglobin</td><td>‚Üì (binds free Hgb)</td></tr>
        </table>
        
        <h3>Classification</h3>
        <table>
            <tr><th>Intrinsic (RBC defect)</th><th>Extrinsic (external cause)</th></tr>
            <tr><td>Membrane: Hereditary spherocytosis, elliptocytosis</td><td>Immune: Warm/cold AIHA</td></tr>
            <tr><td>Enzyme: G6PD, pyruvate kinase</td><td>Microangiopathic: TTP, HUS, DIC</td></tr>
            <tr><td>Hemoglobin: Sickle cell, thalassemia</td><td>Mechanical: Prosthetic valve</td></tr>
            <tr><td>PNH</td><td>Infections: Malaria, Babesia, Clostridium</td></tr>
        </table>
        
        <h3>Direct Antiglobulin Test (DAT/Coombs)</h3>
        <ul>
            <li><strong>Positive:</strong> Immune-mediated hemolysis (AIHA, drug-induced, transfusion reaction)</li>
            <li><strong>Negative:</strong> Non-immune (G6PD, TTP, PNH, hereditary spherocytosis)</li>
        </ul>
    </div>
</div>

<!-- SECTION 5: AIHA -->
<div class="section" id="aiha">
    <div class="section-header">
        <h2>5. Autoimmune Hemolytic Anemia <span class="badge badge-boards">Boards Favorite</span></h2>
    </div>
    <div class="section-content">
        <h3>Warm AIHA</h3>
        <ul>
            <li><strong>Antibody:</strong> IgG (binds at 37¬∞C)</li>
            <li><strong>Site:</strong> Extravascular (spleen)</li>
            <li><strong>Smear:</strong> Spherocytes</li>
            <li><strong>Causes:</strong> Idiopathic, CLL, SLE, drugs (methyldopa, penicillin, cephalosporins)</li>
            <li><strong>Treatment:</strong> Corticosteroids (first-line), rituximab, splenectomy</li>
        </ul>
        
        <h3>Cold Agglutinin Disease</h3>
        <ul>
            <li><strong>Antibody:</strong> IgM (binds at <37¬∞C)</li>
            <li><strong>Site:</strong> Complement-mediated, intravascular</li>
            <li><strong>Causes:</strong> Mycoplasma, EBV, lymphoproliferative disorders</li>
            <li><strong>Treatment:</strong> Avoid cold, rituximab (steroids less effective)</li>
        </ul>
        
        <div class="clinical-pearl">
            <strong>Drug-induced AIHA:</strong> Methyldopa causes warm AIHA via drug-induced autoantibodies. Penicillin causes hapten-mediated hemolysis (drug binds to RBC).
        </div>
    </div>
</div>

<!-- SECTION 6: G6PD -->
<div class="section" id="g6pd">
    <div class="section-header">
        <h2>6. G6PD Deficiency <span class="badge badge-boards">Boards Favorite</span></h2>
    </div>
    <div class="section-content">
        <h3>Overview</h3>
        <ul>
            <li>X-linked recessive</li>
            <li>Most common enzyme deficiency worldwide</li>
            <li>Episodic hemolysis triggered by oxidative stress</li>
        </ul>
        
        <h3>Triggers</h3>
        <div class="mnemonic-box">
            <strong>"Fava beans and drugs that cause havoc":</strong><br>
            Fava beans, Sulfonamides, Dapsone, Primaquine, Nitrofurantoin, Rasburicase, Infections
        </div>
        
        <h3>Clinical Features</h3>
        <ul>
            <li>Acute hemolytic crisis 1-3 days after exposure</li>
            <li>Jaundice, dark urine, back pain</li>
            <li><strong>Smear:</strong> Bite cells, Heinz bodies (require special stain)</li>
        </ul>
        
        <h3>Diagnosis</h3>
        <ul>
            <li><strong>G6PD enzyme assay:</strong> Check when NOT in acute hemolysis (young RBCs have higher G6PD levels)</li>
        </ul>
        
        <h3>Treatment</h3>
        <ul>
            <li>Remove/avoid trigger</li>
            <li>Supportive care, transfusion if severe</li>
            <li>Self-limited once trigger removed</li>
        </ul>
    </div>
</div>

<!-- SECTION 7: SICKLE CELL -->
<div class="section" id="sickle">
    <div class="section-header">
        <h2>7. Sickle Cell Disease <span class="badge badge-boards">High-Yield</span></h2>
    </div>
    <div class="section-content">
        <h3>Pathophysiology</h3>
        <ul>
            <li>HbS (Œ≤S mutation) ‚Üí polymerization under hypoxia/stress ‚Üí sickling</li>
            <li>Hemolysis + vaso-occlusion</li>
        </ul>
        
        <h3>Acute Complications</h3>
        <table>
            <tr><th>Complication</th><th>Features</th><th>Management</th></tr>
            <tr><td><strong>Vaso-occlusive crisis</strong></td><td>Pain in bones, chest, abdomen</td><td>IV fluids, opioids, incentive spirometry</td></tr>
            <tr><td><strong>Acute chest syndrome</strong></td><td>Fever + new infiltrate + respiratory symptoms</td><td>Antibiotics (ceftriaxone + azithromycin), exchange transfusion if severe</td></tr>
            <tr><td><strong>Stroke</strong></td><td>10% of children; ischemic > hemorrhagic</td><td>Exchange transfusion, chronic transfusion program</td></tr>
            <tr><td><strong>Aplastic crisis</strong></td><td>Parvovirus B19 ‚Üí sudden ‚Üì Hgb, ‚Üì retic</td><td>Transfusion, usually self-limited</td></tr>
            <tr><td><strong>Splenic sequestration</strong></td><td>Rapid splenic enlargement, ‚Üì Hgb (children)</td><td>Transfusion, splenectomy if recurrent</td></tr>
            <tr><td><strong>Priapism</strong></td><td>Prolonged painful erection</td><td>Hydration, analgesia, aspiration, exchange transfusion</td></tr>
        </table>
        
        <div class="danger-box">
            <strong>Acute chest syndrome</strong> is the leading cause of death in sickle cell. Consider if fever, hypoxia, new infiltrate. Triggers: infection, fat embolism, hypoventilation.
        </div>
        
        <h3>Chronic Complications</h3>
        <ul>
            <li>Functional asplenia ‚Üí infection risk (encapsulated organisms)</li>
            <li>Pulmonary hypertension</li>
            <li>Chronic kidney disease</li>
            <li>Avascular necrosis (femoral head)</li>
            <li>Retinopathy</li>
            <li>Cholelithiasis (pigmented stones)</li>
        </ul>
        
        <h3>Disease-Modifying Therapies</h3>
        <table>
            <tr><th>Drug</th><th>Mechanism</th><th>Indication</th></tr>
            <tr><td><strong>Hydroxyurea</strong></td><td>‚Üë HbF production</td><td>All patients with recurrent crises</td></tr>
            <tr><td><strong>Voxelotor</strong></td><td>‚Üë Hgb-O2 affinity, prevents sickling</td><td>Hgb-SS</td></tr>
            <tr><td><strong>Crizanlizumab</strong></td><td>Anti-P-selectin, prevents adhesion</td><td>Reduce VOC frequency</td></tr>
            <tr><td><strong>L-glutamine</strong></td><td>Reduces oxidative stress</td><td>Reduce VOC</td></tr>
        </table>
        
        <h3>Curative</h3>
        <ul>
            <li><strong>Allogeneic stem cell transplant:</strong> Curative in select patients</li>
            <li><strong>Gene therapy:</strong> Emerging (exagamglogene autotemcel approved 2023)</li>
        </ul>
    </div>
</div>

<!-- SECTION 8: THALASSEMIA -->
<div class="section" id="thalassemia">
    <div class="section-header">
        <h2>8. Thalassemia <span class="badge badge-boards">Boards Favorite</span></h2>
    </div>
    <div class="section-content">
        <h3>Overview</h3>
        <ul>
            <li>Decreased production of Œ± or Œ≤ globin chains</li>
            <li>Microcytic anemia with normal/elevated iron stores</li>
        </ul>
        
        <h3>Œ≤-Thalassemia</h3>
        <table>
            <tr><th>Type</th><th>Genotype</th><th>Features</th></tr>
            <tr><td><strong>Trait (minor)</strong></td><td>Œ≤/Œ≤‚Å∫ or Œ≤/Œ≤‚Å∞</td><td>Mild microcytic anemia, target cells, ‚Üë HbA2 (>3.5%)</td></tr>
            <tr><td><strong>Intermedia</strong></td><td>Œ≤‚Å∫/Œ≤‚Å∫ or Œ≤‚Å∫/Œ≤‚Å∞</td><td>Moderate anemia, splenomegaly, occasional transfusion</td></tr>
            <tr><td><strong>Major (Cooley's)</strong></td><td>Œ≤‚Å∞/Œ≤‚Å∞</td><td>Severe anemia, transfusion-dependent, iron overload</td></tr>
        </table>
        
        <h3>Œ±-Thalassemia</h3>
        <table>
            <tr><th>Deletions</th><th>Syndrome</th><th>Features</th></tr>
            <tr><td>1 gene (-Œ±/Œ±Œ±)</td><td>Silent carrier</td><td>Normal</td></tr>
            <tr><td>2 genes (--/Œ±Œ± or -Œ±/-Œ±)</td><td>Trait</td><td>Mild microcytic anemia</td></tr>
            <tr><td>3 genes (--/-Œ±)</td><td>HbH disease</td><td>Moderate hemolytic anemia, HbH inclusions</td></tr>
            <tr><td>4 genes (--/--)</td><td>Hb Bart's</td><td>Hydrops fetalis, incompatible with life</td></tr>
        </table>
        
        <div class="high-yield">
            <strong>Mentzer index:</strong> MCV/RBC count. <13 = thalassemia trait; >13 = iron deficiency. Helps differentiate microcytic anemias.
        </div>
        
        <h3>Diagnosis</h3>
        <ul>
            <li><strong>Œ≤-thal trait:</strong> Hgb electrophoresis shows ‚Üë HbA2, ‚Üë HbF</li>
            <li><strong>Œ±-thal:</strong> Normal electrophoresis (need genetic testing or Hb Bart's in newborns)</li>
        </ul>
        
        <h3>Treatment</h3>
        <ul>
            <li><strong>Trait:</strong> No treatment needed; genetic counseling</li>
            <li><strong>Major:</strong> Chronic transfusions + iron chelation (deferoxamine, deferasirox)</li>
            <li><strong>Curative:</strong> Allogeneic HSCT, gene therapy (betibeglogene autotemcel)</li>
        </ul>
    </div>
</div>

<!-- SECTION 9: TTP -->
<div class="section" id="ttp">
    <div class="section-header">
        <h2>9. Thrombotic Thrombocytopenic Purpura <span class="badge badge-danger">Emergency</span></h2>
    </div>
    <div class="section-content">
        <h3>Pathophysiology</h3>
        <ul>
            <li><strong>ADAMTS13 deficiency</strong> (<10% activity)</li>
            <li>Acquired (autoantibody) or hereditary</li>
            <li>Uncleaved ultra-large vWF multimers ‚Üí platelet aggregation ‚Üí microthrombi</li>
        </ul>
        
        <h3>Classic Pentad (rarely complete)</h3>
        <div class="mnemonic-box">
            <strong>FAT RN:</strong> Fever, microangiopathic hemolytic Anemia, Thrombocytopenia, Renal dysfunction, Neurologic changes
        </div>
        
        <h3>Diagnosis</h3>
        <ul>
            <li>Thrombocytopenia + MAHA (schistocytes, elevated LDH, low haptoglobin)</li>
            <li>ADAMTS13 activity <10% (send before plasma exchange)</li>
            <li><strong>PLASMIC score:</strong> Predicts ADAMTS13 deficiency</li>
        </ul>
        
        <div class="danger-box">
            <strong>Do NOT wait for ADAMTS13 results to treat!</strong> Untreated TTP has >90% mortality. Start plasma exchange empirically.
        </div>
        
        <h3>Treatment</h3>
        <ul>
            <li><strong>Plasma exchange (PEX):</strong> First-line, removes antibody and replenishes ADAMTS13</li>
            <li><strong>Corticosteroids:</strong> Prednisone 1 mg/kg</li>
            <li><strong>Caplacizumab:</strong> Anti-vWF nanobody; accelerates platelet recovery</li>
            <li><strong>Rituximab:</strong> For refractory/relapsing cases</li>
        </ul>
        
        <div class="high-yield">
            <strong>TTP vs HUS:</strong> TTP = neuro predominant, ADAMTS13 <10%. HUS = renal predominant, often Shiga toxin (STEC-HUS).
        </div>
    </div>
</div>

<!-- SECTION 10: HIT -->
<div class="section" id="hit">
    <div class="section-header">
        <h2>10. Heparin-Induced Thrombocytopenia <span class="badge badge-danger">Emergency</span></h2>
    </div>
    <div class="section-content">
        <h3>Types</h3>
        <table>
            <tr><th>Type</th><th>Features</th></tr>
            <tr><td><strong>Type 1</strong></td><td>Non-immune, mild drop in platelets, benign</td></tr>
            <tr><td><strong>Type 2 (HIT)</strong></td><td>Immune-mediated, prothrombotic, clinically significant</td></tr>
        </table>
        
        <h3>HIT (Type 2)</h3>
        <ul>
            <li>Antibodies to PF4-heparin complexes</li>
            <li>Platelet activation ‚Üí <strong>thrombosis</strong> (50% if untreated)</li>
            <li>Onset: 5-10 days after heparin start (or <24h if prior exposure)</li>
            <li>Platelet drop ‚â•50% from baseline</li>
        </ul>
        
        <h3>4T Score</h3>
        <table>
            <tr><th>Category</th><th>2 Points</th><th>1 Point</th><th>0 Points</th></tr>
            <tr><td>Thrombocytopenia</td><td>>50% drop, nadir ‚â•20</td><td>30-50% drop, nadir 10-19</td><td><30% drop, nadir <10</td></tr>
            <tr><td>Timing</td><td>Day 5-10 or <1d if prior</td><td>>10 days or unclear</td><td><4 days without prior</td></tr>
            <tr><td>Thrombosis</td><td>New thrombosis</td><td>Progressive/recurrent</td><td>None</td></tr>
            <tr><td>Other cause</td><td>No other cause</td><td>Possible other cause</td><td>Definite other cause</td></tr>
        </table>
        <p>0-3: Low probability; 4-5: Intermediate; 6-8: High</p>
        
        <h3>Diagnosis</h3>
        <ul>
            <li><strong>PF4-heparin ELISA:</strong> High sensitivity, lower specificity</li>
            <li><strong>Serotonin release assay (SRA):</strong> Gold standard, high specificity</li>
        </ul>
        
        <h3>Management</h3>
        <ul>
            <li><strong>Stop all heparin immediately</strong> (including flushes)</li>
            <li><strong>Start non-heparin anticoagulant:</strong> Argatroban, bivalirudin, fondaparinux</li>
            <li><strong>Do NOT give warfarin</strong> until platelets >150 (causes skin necrosis)</li>
            <li>Transition to DOAC or warfarin when stable</li>
        </ul>
        
        <div class="danger-box">
            HIT is a <strong>prothrombotic</strong> state despite low platelets. Thrombosis risk 50% if untreated. Always anticoagulate, never transfuse platelets.
        </div>
    </div>
</div>

<!-- Continue with Sections 11-50 -->
<!-- Including: ITP, DIC, Hemophilia, vWD, Hypercoagulable states, ALL, AML, CLL, CML, Hodgkin/NHL, Multiple Myeloma, MDS, MPN, Transfusion reactions, Oncologic emergencies, etc. -->

<!-- SECTION 11: ITP -->
<div class="section" id="itp">
    <div class="section-header">
        <h2>11. Immune Thrombocytopenic Purpura <span class="badge badge-common">Common</span></h2>
    </div>
    <div class="section-content">
        <h3>Overview</h3>
        <ul>
            <li>Autoantibodies against platelet glycoproteins (GPIIb/IIIa)</li>
            <li>Isolated thrombocytopenia; normal WBC and Hgb</li>
            <li>Diagnosis of exclusion</li>
        </ul>
        
        <h3>Clinical Features</h3>
        <ul>
            <li>Mucocutaneous bleeding (petechiae, purpura, epistaxis, gingival)</li>
            <li>No splenomegaly (vs hypersplenism)</li>
        </ul>
        
        <h3>Workup</h3>
        <ul>
            <li>CBC, peripheral smear (isolated thrombocytopenia, large platelets)</li>
            <li>HIV, HCV testing (can cause ITP)</li>
            <li>H. pylori (treat if positive)</li>
            <li>Bone marrow biopsy: Only if atypical features or >60 years</li>
        </ul>
        
        <h3>Treatment</h3>
        <table>
            <tr><th>Indication</th><th>Treatment</th></tr>
            <tr><td>Plt >30, asymptomatic</td><td>Observation</td></tr>
            <tr><td>Plt <30 or bleeding</td><td>Corticosteroids (prednisone or dexamethasone)</td></tr>
            <tr><td>Severe bleeding</td><td>IVIG + steroids ¬± platelet transfusion</td></tr>
            <tr><td>Refractory</td><td>Rituximab, TPO-RA (romiplostim, eltrombopag), splenectomy</td></tr>
        </table>
    </div>
</div>

<!-- SECTION 12: DIC -->
<div class="section" id="dic">
    <div class="section-header">
        <h2>12. Disseminated Intravascular Coagulation <span class="badge badge-danger">Emergency</span></h2>
    </div>
    <div class="section-content">
        <h3>Pathophysiology</h3>
        <ul>
            <li>Systemic activation of coagulation ‚Üí widespread microvascular thrombosis</li>
            <li>Consumption of platelets and clotting factors ‚Üí bleeding</li>
        </ul>
        
        <h3>Causes</h3>
        <ul>
            <li><strong>Sepsis</strong> (most common)</li>
            <li>Malignancy (especially APL, adenocarcinoma)</li>
            <li>Trauma, burns</li>
            <li>Obstetric complications (placental abruption, amniotic fluid embolism)</li>
            <li>Transfusion reactions</li>
        </ul>
        
        <h3>Laboratory Findings</h3>
        <table>
            <tr><th>Test</th><th>Finding</th></tr>
            <tr><td>Platelets</td><td>‚Üì</td></tr>
            <tr><td>PT/PTT</td><td>‚Üë</td></tr>
            <tr><td>Fibrinogen</td><td>‚Üì</td></tr>
            <tr><td>D-dimer</td><td>‚Üë‚Üë</td></tr>
            <tr><td>Smear</td><td>Schistocytes</td></tr>
        </table>
        
        <h3>Treatment</h3>
        <ul>
            <li><strong>Treat underlying cause</strong> (most important)</li>
            <li><strong>If bleeding:</strong> Platelets (if <50), FFP (if elevated INR), cryoprecipitate (if fibrinogen <100)</li>
            <li><strong>Anticoagulation:</strong> Consider if thrombosis predominant (rare)</li>
        </ul>
    </div>
</div>

<!-- SECTION 13: HEMOPHILIA -->
<div class="section" id="hemophilia">
    <div class="section-header">
        <h2>13. Hemophilia A & B <span class="badge badge-boards">High-Yield</span></h2>
    </div>
    <div class="section-content">
        <h3>Overview</h3>
        <table>
            <tr><th>Type</th><th>Deficiency</th><th>Inheritance</th></tr>
            <tr><td>Hemophilia A</td><td>Factor VIII</td><td>X-linked recessive</td></tr>
            <tr><td>Hemophilia B (Christmas)</td><td>Factor IX</td><td>X-linked recessive</td></tr>
        </table>
        
        <h3>Clinical Features</h3>
        <ul>
            <li>Deep tissue bleeding: hemarthrosis (hallmark), muscle hematomas, retroperitoneal</li>
            <li>Delayed bleeding after trauma</li>
            <li>No petechiae (platelet-type bleeding)</li>
        </ul>
        
        <h3>Laboratory Findings</h3>
        <ul>
            <li><strong>PTT:</strong> Prolonged</li>
            <li><strong>PT:</strong> Normal</li>
            <li><strong>Mixing study:</strong> Corrects (factor deficiency, not inhibitor)</li>
            <li>Confirm with factor VIII/IX activity levels</li>
        </ul>
        
        <h3>Severity</h3>
        <table>
            <tr><th>Severity</th><th>Factor Level</th><th>Bleeding</th></tr>
            <tr><td>Mild</td><td>5-40%</td><td>After major trauma/surgery</td></tr>
            <tr><td>Moderate</td><td>1-5%</td><td>After minor trauma</td></tr>
            <tr><td>Severe</td><td><1%</td><td>Spontaneous</td></tr>
        </table>
        
        <h3>Treatment</h3>
        <ul>
            <li><strong>Factor replacement:</strong> Recombinant factor VIII or IX</li>
            <li><strong>Desmopressin (DDAVP):</strong> For mild hemophilia A (releases vWF and factor VIII)</li>
            <li><strong>Emicizumab:</strong> Bispecific antibody mimicking factor VIII (for hemophilia A prophylaxis)</li>
            <li><strong>Avoid NSAIDs and IM injections</strong></li>
        </ul>
        
        <div class="clinical-pearl">
            Up to 30% of severe hemophilia A patients develop factor VIII inhibitors (antibodies). Treat with bypassing agents (factor VIIa, FEIBA).
        </div>
    </div>
</div>

<!-- SECTION 14: vWD -->
<div class="section" id="vwd">
    <div class="section-header">
        <h2>14. von Willebrand Disease <span class="badge badge-common">Common</span></h2>
    </div>
    <div class="section-content">
        <h3>Overview</h3>
        <ul>
            <li>Most common inherited bleeding disorder</li>
            <li>vWF: Mediates platelet adhesion, carries factor VIII</li>
        </ul>
        
        <h3>Types</h3>
        <table>
            <tr><th>Type</th><th>Defect</th><th>Labs</th></tr>
            <tr><td><strong>Type 1 (75%)</strong></td><td>Partial quantitative deficiency</td><td>‚Üì vWF:Ag, ‚Üì vWF:RCo</td></tr>
            <tr><td><strong>Type 2</strong></td><td>Qualitative defect</td><td>Variable; 2A, 2B, 2M, 2N subtypes</td></tr>
            <tr><td><strong>Type 3</strong></td><td>Complete deficiency (severe)</td><td>Absent vWF, very low factor VIII</td></tr>
        </table>
        
        <h3>Clinical Features</h3>
        <ul>
            <li>Mucocutaneous bleeding (menorrhagia, epistaxis, easy bruising)</li>
            <li>Bleeding after dental procedures, surgery</li>
        </ul>
        
        <h3>Laboratory Findings</h3>
        <ul>
            <li>PTT: May be prolonged (if factor VIII low)</li>
            <li>Bleeding time: Prolonged (if performed)</li>
            <li>vWF:Ag (antigen) and vWF:RCo (activity) decreased</li>
        </ul>
        
        <h3>Treatment</h3>
        <ul>
            <li><strong>DDAVP:</strong> First-line for Type 1 (releases vWF from endothelium)</li>
            <li><strong>vWF-containing factor concentrates:</strong> For Type 2, Type 3, or major bleeding</li>
            <li><strong>Antifibrinolytics:</strong> Tranexamic acid for mucosal bleeding</li>
        </ul>
        
        <div class="danger-box">
            <strong>DDAVP is contraindicated in Type 2B vWD</strong> ‚Äî can worsen thrombocytopenia (mutant vWF binds platelets excessively).
        </div>
    </div>
</div>

<!-- SECTION 15: VTE/HYPERCOAGULABLE -->
<div class="section" id="thrombosis">
    <div class="section-header">
        <h2>15. Hypercoagulable States <span class="badge badge-boards">High-Yield</span></h2>
    </div>
    <div class="section-content">
        <h3>Inherited Thrombophilias</h3>
        <table>
            <tr><th>Condition</th><th>Mechanism</th><th>Risk</th></tr>
            <tr><td><strong>Factor V Leiden</strong></td><td>Resistance to activated protein C</td><td>Most common; 5-7√ó VTE risk (heterozygous)</td></tr>
            <tr><td><strong>Prothrombin G20210A</strong></td><td>Increased prothrombin levels</td><td>3√ó VTE risk</td></tr>
            <tr><td><strong>Protein C/S deficiency</strong></td><td>‚Üì Anticoagulant proteins</td><td>Warfarin-induced skin necrosis</td></tr>
            <tr><td><strong>Antithrombin deficiency</strong></td><td>‚Üì Heparin cofactor</td><td>Heparin resistance</td></tr>
        </table>
        
        <h3>Acquired Thrombophilias</h3>
        <table>
            <tr><th>Condition</th><th>Features</th></tr>
            <tr><td><strong>Antiphospholipid syndrome</strong></td><td>Arterial + venous thrombosis, pregnancy loss, lupus anticoagulant, anticardiolipin, anti-Œ≤2GP1</td></tr>
            <tr><td><strong>Malignancy</strong></td><td>Unprovoked VTE; consider cancer screening</td></tr>
            <tr><td><strong>PNH</strong></td><td>Venous thrombosis (unusual sites), hemolysis, cytopenias</td></tr>
            <tr><td><strong>Myeloproliferative neoplasms</strong></td><td>Splanchnic vein thrombosis, erythromelalgia</td></tr>
        </table>
        
        <h3>When to Test</h3>
        <ul>
            <li>VTE at young age (<45)</li>
            <li>Recurrent VTE</li>
            <li>VTE at unusual site (mesenteric, cerebral)</li>
            <li>Strong family history</li>
            <li>Warfarin-induced skin necrosis (protein C/S)</li>
        </ul>
        
        <div class="clinical-pearl">
            Testing during acute VTE or on anticoagulation gives unreliable results. Wait 2-4 weeks after completing anticoagulation.
        </div>
    </div>
</div>

<!-- Continue with remaining sections for Leukemia, Lymphoma, Myeloma, etc. -->

<div class="section" id="leukemia">
    <div class="section-header">
        <h2>16. Acute Myeloid Leukemia <span class="badge badge-boards">High-Yield</span></h2>
    </div>
    <div class="section-content">
        <h3>Overview</h3>
        <ul>
            <li>Clonal expansion of myeloid blasts (‚â•20% in marrow)</li>
            <li>Most common acute leukemia in adults</li>
        </ul>
        
        <h3>Clinical Features</h3>
        <ul>
            <li><strong>Bone marrow failure:</strong> Anemia (fatigue), thrombocytopenia (bleeding), neutropenia (infections)</li>
            <li><strong>Leukostasis:</strong> WBC >100K ‚Üí pulmonary/CNS symptoms (emergency)</li>
            <li><strong>DIC:</strong> Especially APL</li>
            <li><strong>Gingival hyperplasia:</strong> Monocytic subtypes (M4, M5)</li>
            <li><strong>Auer rods:</strong> Pathognomonic for AML</li>
        </ul>
        
        <h3>Key Subtypes</h3>
        <table>
            <tr><th>Subtype</th><th>Genetics</th><th>Features</th></tr>
            <tr><td><strong>APL (M3)</strong></td><td>t(15;17) PML-RARA</td><td>DIC, treat with ATRA + arsenic, good prognosis</td></tr>
            <tr><td><strong>Core binding factor</strong></td><td>t(8;21), inv(16)</td><td>Favorable prognosis</td></tr>
            <tr><td><strong>FLT3-mutated</strong></td><td>FLT3-ITD</td><td>Poor prognosis, midostaurin</td></tr>
            <tr><td><strong>NPM1-mutated</strong></td><td>NPM1</td><td>Favorable (if no FLT3)</td></tr>
        </table>
        
        <div class="danger-box">
            <strong>APL emergency:</strong> t(15;17). High DIC and bleeding risk. Start ATRA immediately on suspicion ‚Äî don't wait for cytogenetics.
        </div>
        
        <h3>Treatment</h3>
        <ul>
            <li><strong>Induction:</strong> "7+3" (cytarabine 7 days + anthracycline 3 days)</li>
            <li><strong>Consolidation:</strong> High-dose cytarabine or allogeneic HSCT</li>
            <li><strong>Targeted therapies:</strong> FLT3 inhibitors (midostaurin), IDH inhibitors, venetoclax</li>
        </ul>
    </div>
</div>

<div class="section" id="cml">
    <div class="section-header">
        <h2>17. Chronic Myeloid Leukemia <span class="badge badge-boards">Boards Favorite</span></h2>
    </div>
    <div class="section-content">
        <h3>Pathophysiology</h3>
        <ul>
            <li><strong>t(9;22) Philadelphia chromosome</strong> ‚Üí BCR-ABL1 fusion</li>
            <li>Constitutively active tyrosine kinase</li>
        </ul>
        
        <h3>Clinical Features</h3>
        <ul>
            <li>Often asymptomatic (incidental leukocytosis)</li>
            <li>Fatigue, weight loss, night sweats</li>
            <li><strong>Massive splenomegaly</strong></li>
            <li>WBC very high (often >100K) with left shift, basophilia</li>
        </ul>
        
        <h3>Phases</h3>
        <table>
            <tr><th>Phase</th><th>Features</th></tr>
            <tr><td>Chronic</td><td><10% blasts, most patients at diagnosis</td></tr>
            <tr><td>Accelerated</td><td>10-19% blasts, basophils >20%, other criteria</td></tr>
            <tr><td>Blast crisis</td><td>‚â•20% blasts (myeloid or lymphoid)</td></tr>
        </table>
        
        <h3>Diagnosis</h3>
        <ul>
            <li>CBC with differential showing leukocytosis, left shift, basophilia</li>
            <li>Low LAP score (vs leukemoid reaction)</li>
            <li><strong>Confirm:</strong> BCR-ABL1 by FISH or PCR, cytogenetics for Ph chromosome</li>
        </ul>
        
        <h3>Treatment</h3>
        <ul>
            <li><strong>Tyrosine kinase inhibitors (TKIs):</strong> Imatinib, dasatinib, nilotinib, bosutinib</li>
            <li>Monitor BCR-ABL1 transcripts by PCR</li>
            <li>Deep molecular response ‚Üí possible TKI discontinuation</li>
            <li>Allogeneic HSCT for TKI-resistant or blast crisis</li>
        </ul>
        
        <div class="high-yield">
            TKIs have transformed CML into a chronic manageable disease. Most patients achieve near-normal life expectancy with treatment.
        </div>
    </div>
</div>

<div class="section" id="lymphoma">
    <div class="section-header">
        <h2>18. Hodgkin Lymphoma <span class="badge badge-boards">High-Yield</span></h2>
    </div>
    <div class="section-content">
        <h3>Pathology</h3>
        <ul>
            <li><strong>Reed-Sternberg cells:</strong> "Owl-eye" appearance, CD15+/CD30+</li>
            <li>Bimodal age distribution (20s and >55)</li>
        </ul>
        
        <h3>Clinical Features</h3>
        <ul>
            <li><strong>Painless lymphadenopathy</strong> (cervical most common)</li>
            <li><strong>B symptoms:</strong> Fever >38¬∞C, night sweats, >10% weight loss in 6 months</li>
            <li>Alcohol-induced lymph node pain (rare but classic)</li>
            <li>Contiguous spread (vs NHL)</li>
        </ul>
        
        <h3>Subtypes</h3>
        <table>
            <tr><th>Subtype</th><th>Features</th></tr>
            <tr><td><strong>Nodular sclerosis</strong></td><td>Most common (70%), young adults, mediastinal</td></tr>
            <tr><td><strong>Mixed cellularity</strong></td><td>Older adults, EBV associated</td></tr>
            <tr><td><strong>Lymphocyte-rich</strong></td><td>Best prognosis</td></tr>
            <tr><td><strong>Lymphocyte-depleted</strong></td><td>Worst prognosis, HIV-associated</td></tr>
        </table>
        
        <h3>Staging (Ann Arbor)</h3>
        <table>
            <tr><th>Stage</th><th>Definition</th></tr>
            <tr><td>I</td><td>Single lymph node region</td></tr>
            <tr><td>II</td><td>‚â•2 regions, same side of diaphragm</td></tr>
            <tr><td>III</td><td>Both sides of diaphragm</td></tr>
            <tr><td>IV</td><td>Extranodal involvement (marrow, liver)</td></tr>
        </table>
        <p>A = no B symptoms; B = B symptoms present</p>
        
        <h3>Treatment</h3>
        <ul>
            <li><strong>Limited stage (I-II):</strong> ABVD √ó 2-4 cycles ¬± radiation</li>
            <li><strong>Advanced (III-IV):</strong> ABVD √ó 6 cycles or escalated BEACOPP</li>
            <li><strong>Relapsed:</strong> Salvage chemo ‚Üí autologous HSCT</li>
            <li><strong>Brentuximab vedotin:</strong> Anti-CD30 ADC for relapsed</li>
            <li><strong>Checkpoint inhibitors:</strong> PD-1 inhibitors for refractory</li>
        </ul>
        
        <div class="clinical-pearl">
            Hodgkin lymphoma is highly curable (>80% overall). Long-term survivors need monitoring for secondary malignancies (breast, lung) and cardiac disease from treatment.
        </div>
    </div>
</div>

<div class="section" id="myeloma">
    <div class="section-header">
        <h2>19. Multiple Myeloma <span class="badge badge-boards">High-Yield</span></h2>
    </div>
    <div class="section-content">
        <h3>Overview</h3>
        <ul>
            <li>Clonal plasma cell neoplasm producing monoclonal protein</li>
            <li>Median age 70 years; more common in Black patients</li>
        </ul>
        
        <h3>Clinical Features ‚Äî CRAB</h3>
        <div class="mnemonic-box">
            <strong>C</strong>alcium elevation (>11)<br>
            <strong>R</strong>enal insufficiency (Cr >2 or CrCl <40)<br>
            <strong>A</strong>nemia (Hgb <10 or 2g below normal)<br>
            <strong>B</strong>one lesions (lytic, osteoporosis, pathologic fractures)
        </div>
        
        <h3>Other Features</h3>
        <ul>
            <li><strong>Infections:</strong> Impaired humoral immunity</li>
            <li><strong>Hyperviscosity:</strong> Visual changes, bleeding, neurologic symptoms</li>
            <li><strong>Amyloidosis:</strong> AL type (light chain)</li>
            <li><strong>Neuropathy</strong></li>
        </ul>
        
        <h3>Diagnosis</h3>
        <ul>
            <li><strong>SPEP/UPEP:</strong> M-spike (monoclonal protein)</li>
            <li><strong>Serum free light chains:</strong> Kappa/lambda ratio</li>
            <li><strong>Bone marrow biopsy:</strong> ‚â•10% clonal plasma cells</li>
            <li><strong>Skeletal survey or PET/CT:</strong> Lytic lesions</li>
        </ul>
        
        <h3>Diagnostic Criteria (‚â•1 CRAB or biomarker)</h3>
        <ul>
            <li>Clonal plasma cells ‚â•10% OR biopsy-proven plasmacytoma</li>
            <li>PLUS ‚â•1 myeloma-defining event: CRAB or biomarker (‚â•60% plasma cells, FLC ratio ‚â•100, >1 MRI lesion)</li>
        </ul>
        
        <h3>Treatment</h3>
        <ul>
            <li><strong>Transplant-eligible:</strong> Induction (VRd: bortezomib, lenalidomide, dexamethasone) ‚Üí autologous HSCT ‚Üí maintenance</li>
            <li><strong>Transplant-ineligible:</strong> VRd or Dara-VRd, continue until progression</li>
            <li><strong>Supportive:</strong> Bisphosphonates, pain control, infection prophylaxis</li>
        </ul>
        
        <div class="danger-box">
            Avoid NSAIDs and nephrotoxins. Light chain cast nephropathy is a medical emergency ‚Äî treat myeloma and consider plasmapheresis.
        </div>
    </div>
</div>

<!-- Board Pearls -->
<div class="section" id="pearls">
    <div class="section-header">
        <h2>50. High-Yield Board Pearls</h2>
    </div>
    <div class="section-content">
        <h3>Anemia</h3>
        <ul>
            <li>üíé Low ferritin = iron deficiency. Normal ferritin with inflammation doesn't rule it out.</li>
            <li>üíé B12 deficiency can cause neuro symptoms WITHOUT anemia. Check MMA if borderline.</li>
            <li>üíé Spherocytes + positive DAT = warm AIHA. Spherocytes + negative DAT = hereditary spherocytosis.</li>
            <li>üíé G6PD assay is falsely normal during acute hemolysis ‚Äî retest later.</li>
        </ul>
        
        <h3>Bleeding Disorders</h3>
        <ul>
            <li>üíé Prolonged PTT + normal PT + mixing corrects = factor deficiency (VIII, IX, XI, XII).</li>
            <li>üíé Prolonged PTT + doesn't correct = inhibitor (lupus anticoagulant or factor inhibitor).</li>
            <li>üíé vWD: Most common inherited bleeding disorder. DDAVP for Type 1.</li>
            <li>üíé DIC: Treat the underlying cause. Replace products only if bleeding.</li>
        </ul>
        
        <h3>Thrombosis</h3>
        <ul>
            <li>üíé HIT = prothrombotic! Stop heparin AND start non-heparin anticoagulant.</li>
            <li>üíé TTP: Don't wait for ADAMTS13 ‚Äî start plasma exchange immediately.</li>
            <li>üíé Warfarin skin necrosis = protein C/S deficiency. Bridge with heparin.</li>
        </ul>
        
        <h3>Leukemia</h3>
        <ul>
            <li>üíé APL [t(15;17)] = DIC. Start ATRA immediately on suspicion.</li>
            <li>üíé CML = Philadelphia chromosome t(9;22), BCR-ABL1. TKIs are curative.</li>
            <li>üíé CLL = CD5+/CD23+ B-cells. Watch and wait if asymptomatic.</li>
            <li>üíé Auer rods = AML (not ALL).</li>
        </ul>
        
        <h3>Lymphoma</h3>
        <ul>
            <li>üíé Reed-Sternberg cells = Hodgkin. CD15+/CD30+.</li>
            <li>üíé "Starry sky" pattern = Burkitt lymphoma. t(8;14) c-MYC.</li>
            <li>üíé Hodgkin spreads contiguously; NHL spreads hematogenously.</li>
        </ul>
        
        <h3>Myeloma</h3>
        <ul>
            <li>üíé CRAB criteria: Calcium, Renal, Anemia, Bone lesions.</li>
            <li>üíé Rouleaux formation on smear = myeloma or Waldenstr√∂m's.</li>
            <li>üíé Lytic lesions on skeletal survey (not bone scan ‚Äî no blastic activity).</li>
        </ul>
        
        <h3>Transfusion</h3>
        <ul>
            <li>üíé TRALI = noncardiogenic pulmonary edema within 6h of transfusion.</li>
            <li>üíé TACO = volume overload. Diuretics help (vs TRALI where they don't).</li>
            <li>üíé Febrile non-hemolytic = most common reaction. Cytokines in product.</li>
        </ul>
    </div>
</div>

<button class="back-to-top" id="backToTop" onclick="scrollToTop()">‚Üë</button>

<footer>
    <h3 style="margin: 0 0 10px;">ü©∏ ABIM Hematology/Oncology Study Guide</h3>
    <p style="opacity: 0.9; font-size: 0.9rem;">ASH ‚Ä¢ ASCO ‚Ä¢ NCCN Guidelines</p>
    <div style="margin-top: 20px;">
        <a href="index.html">üìö Clinical Suite</a>
        <a href="im_guide.html">ü©∫ IM Guide</a>
        <a href="pulmonology_study_guide.html">ü´Å Pulm</a>
        <a href="endocrinology_study_guide.html">üî¨ Endo</a>
    </div>
</footer>

<script>
    const searchBox = document.getElementById('searchBox');
    searchBox.addEventListener('input', function() {
        const query = this.value.toLowerCase();
        document.querySelectorAll('.section').forEach(section => {
            section.style.display = (query === '' || section.textContent.toLowerCase().includes(query)) ? 'block' : 'none';
        });
    });
    
    const backToTopBtn = document.getElementById('backToTop');
    window.addEventListener('scroll', () => backToTopBtn.classList.toggle('show', window.pageYOffset > 400));
    function scrollToTop() { window.scrollTo({ top: 0, behavior: 'smooth' }); }
    
    document.querySelectorAll('.section-header').forEach(header => {
        header.addEventListener('click', () => header.parentElement.classList.toggle('collapsed'));
    });
</script>

</body>
</html>
